Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Bladder Cancer, Version 3.2024
Flaig, Thomas W. , Abern, Michael, Agarwal, Neeraj , Bangs, Rick , Buyyounouski, Mark K. , Chang, Paul, Friedlander, Terence W. , Greenberg, Richard E. , Guru, Khurshid A. , Herr, Harry W., Hoffman‐Censits, Jean , Kaimakliotis, Hristos Z. , Kishan, Amar U. , Kundu, Shilajit , Lele, Subodh M. , Mamtani, Ronac , Michalski, Jeff M., Montgomery, Jeffrey S., Patterson, Anthony, Peyton, Charles C. , Preston, Mark A. , Sexton, Wade J. , Stewart, Tyler F. , Sundi, Debasish , Tollefson, Matthew K. , Wright, Jonathan L. , Cassara, Carly J., Gurski, Lisa A., Tollefson, Matthew, Spiess, Philippe E. , Agarwal, Neeraj , Chan, Kevin , Chang, Sam S. , Chang, Paul, Mian, Omar Y. , Parikh, Mamta , Plimack, Elizabeth R. , Richards, Kyle A. , Siefker-Radtke, Arlene Odelia , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 16, 2024 | Volume: 22 | Issue: 4 | Pages: 216-225

10.6004/jnccn.2024.0024 | PMID 38754471 Get It

Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non–muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
National Emergency Tele-Critical Care in a Pandemic: Barriers and Solutions
Pamplin, Jeremy , Gray, B.A. Mitchell, Quinn, Matthew , Little, Jeanette R , Subramanian, Sanjay , Farmer, Joseph C. , Ries, Michael, Scott, Benjamin , Participants, for the Governance Stakeholder Working Group and National Emergency Tele-Critical Care Network Team, Armaignac, Donna Lee , Polk, Travis M. , Colombo, Christopher J. , Participants, for the Governance Stakeholder Working Group and National Emergency Tele-Critical Care Network Team

Mayo Clinic

Critical Care Explorations | May 15, 2024 | Volume: 6 | Issue: 5 | Pages: e1091

10.1097/cce.0000000000001091 | PMID 38746740 Get It

The COVID-19 pandemic caused tremendous disruption to the U.S. healthcare system and nearly crippled some hospitals during large patient surges. Limited ICU beds across the country further exacerbated these challenges. Telemedicine, specifically tele-critical care (TCC), can expand a hospital’s clinical capabilities through remote expertise and increase capacity by offloading some monitoring to remote teams. Unfortunately, the rapid deployment of telemedicine, especially TCC, is constrained by multiple barriers. In the summer of 2020, to support the National Emergency Tele-Critical Care Network (NETCCN) deployment, more than 50 national leaders in applying telemedicine technologies to critical care assembled to provide their opinions about barriers to NETCCN implementation and strategies to overcome them. Through consensus, these experts developed white papers that formed the basis of this article. Herein, the authors share their experience and propose multiple solutions to barriers presented by laws, local policies and cultures, and individual perspectives according to a minimum, better, best paradigm for TCC delivery in the setting of a national disaster. Cross-state licensure and local privileging of virtual experts were identified as the most significant barriers to rapid deployment of services, whereas refining the model of TCC to achieve the best outcomes and defining the best financial model is the most significant for long-term success. Ultimately, we conclude that a rapidly deployable national telemedicine response system is achievable.
Cochlear Implantation in Patients With Osteolytic Labyrinthitis: A Case Series
Thedinger, William B., Dornhoffer, James R. , Merlino, Dante J. , Lane, John I. , Carlson, Matthew L. , Kircher, Matthew L.

Mayo Clinic

Otology & Neurotology | May 10, 2024 | Volume: 45 | Issue: 5 | Pages: e406-e410

10.1097/mao.0000000000004193 | PMID 38728556 Get It

Objective To describe the rare process of osteolytic labyrinthitis, previously referred to as labyrinthine sequestrum, which involves progressive obliteration of the bony and membranous labyrinth with eventual supplantation with soft tissue and, in some cases, bony sequestrum. Patients Three patients with diverse presentations of osteolytic labyrinthitis from two tertiary care academic medical centers. Intervention(s) Case series report analyzing the relevant clinical, radiologic, pathologic, and surgical data on our patients with osteolytic labyrinthitis and comparing these index cases to the existing literature. Main Outcome Measure(s) We describe the varying image findings seen in osteolytic labyrinthitis on computed tomography and magnetic resonance imaging. Also, we report successful surgical intervention and hearing rehabilitation with cochlear implantation in patients with osteolytic labyrinthitis. Results Our three patients presented with profound sudden sensorineural hearing loss and vertigo consistent with labyrinthitis. None of the three patients had a history of chronic otitis media. Imaging workup revealed varying degrees of erosion to the otic capsule bone demonstrating the spectrum of disease seen in osteolytic labyrinthitis. Although two cases showed osteolytic changes to the semicircular canals and vestibule, the first case revealed frank bony sequestrum within the obliterated labyrinth. The three cases were taken for surgical debridement and cochlear implantation. Conclusions We propose the new term, osteolytic labyrinthitis—previously referred to as labyrinthine sequestrum—to describe the rare spectrum of disease characterized by destruction of the osseous and membranous labyrinth and potential supplantation with bony sequestrum. Cochlear implantation is a viable option in selected patients with osteolytic labyrinthitis.
Repeat Radiosurgery for Sporadic Vestibular Schwannoma After Primary Radiosurgical Failure: An International Multi-institutional Investigation
Khandalavala, Karl R. , Herberg, Hans A., Kay‐Rivest, Emily , Moore, Lindsay S. , Marinelli, John P. , Lund‐Johansen, Morten , Kosaraju, Nikitha , Lohse, Christine M. , Kutz, Walter, Maria, Peter L. Santa , Golfinos, John G. , Carlson, Matthew L. , Tveiten, Øystein Vesterli , Link, Michael J. , Yancey, Kristen L. , Kondziolka, Douglas

Mayo Clinic

Otology & Neurotology | May 10, 2024 | Volume: 45 | Issue: 5 | Pages: 587-593

10.1097/mao.0000000000004189 | PMID 38728563 Get It

Objective To describe outcomes of patients with sporadic vestibular schwannoma (VS) who underwent repeat stereotactic radiosurgery (SRS) after primary SRS failure. Study Design Multi-institutional historical cohort study. Setting Five tertiary care referral centers. Patients Adults ≥18 years old with sporadic VS. Intervention Primary and repeat treatment with SRS. Main Outcome Measure Microsurgery-free survival after repeat SRS. Results Across institutions, 32 patients underwent repeat SRS after primary SRS. Most patients (74%) had tumors with cerebellopontine angle extension at primary SRS (median size, 13.5 mm [interquartile range, 7.5–18.8] mm). After primary SRS, patients underwent repeat SRS at a median of 4.8 years (interquartile range, 3.2–5.7 yr). For treatment modality, 30 (94%) patients received gamma knife for primary treatment and 31 (97%) patients received gamma knife as their repeat treatment. Median tumor volume increased from 0.970 cm3 at primary SRS to 2.200 cm3 at repeat SRS. Facial nerve function worsened in two patients after primary SRS and in two patients after repeat SRS. There were no instances of intracranial complications after repeat SRS. Microsurgery-free survival rates (95% confidence interval; number still at risk) at 1, 3, and 5 years after repeat SRS were 97% (90–100%, 24), 84% (71–100%, 13), and 68% (48–96%, 6), respectively. There was one occurrence of malignancy diagnosed after repeat radiosurgery. Conclusion Overall, repeat SRS for sporadic VS has comparable risk profile, but lower rates of tumor control, compared with primary SRS.
Stapedotomy Versus Cochlear Implantation for Far Advanced Otosclerosis: Insights From a Patient With Matched Preoperative and Postoperative Function
Khandalavala, Karl R. , Dornhoffer, Jim R., Lane, John I. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | May 10, 2024 | Volume: 45 | Issue: 5 | Pages: e381-e384

10.1097/mao.0000000000004197 | PMID 38728553 Get It

Objective To examine patient preference after stapedotomy versus cochlear implantation in a unique case of a patient with symmetrical profound mixed hearing loss and similar postoperative speech perception improvement. Patients An adult patient with bilateral symmetrical far advanced otosclerosis, with profound mixed hearing loss. Intervention Stapedotomy in the left ear, cochlear implantation in the right ear. Main Outcome Measure Performance on behavioral audiometry, and subjective report of hearing and intervention preference. Results A patient successfully underwent left stapedotomy and subsequent cochlear implantation on the right side, per patient preference. Preoperative audiometric characteristics were similar between ears (pure-tone average [PTA] [R: 114; L: 113 dB]; word recognition score [WRS]: 22%). Postprocedural audiometry demonstrated significant improvement after stapedotomy (PTA: 59 dB, WRS: 75%) and from cochlear implant (PTA: 20 dB, WRS: 60%). The patient subjectively reported a preference for the cochlear implant ear despite having substantial gains from stapedotomy. A nuanced discussion highlighting potentially overlooked benefits of cochlear implants in far advanced otosclerosis is conducted. Conclusion In comparison with stapedotomy and hearing aids, cochlear implantation generally permits greater access to sound among patients with far advanced otosclerosis. Though the cochlear implant literature mainly focuses on speech perception outcomes, an underappreciated benefit of cochlear implantation is the high likelihood of achieving “normal” sound levels across the audiogram.
Self-scheduling Medical Visits in a Multispecialty, Multisite Medical Practice: Complexity, Challenges, and Successes
North, Frederick , Buss, Rebecca J , Nelson, Elissa M , Thompson, Matthew C , Garrison, Gregory M. , Crum, Brian A. , Buss, Rebecca , Pecina, Jennifer , Garrison, Gregory M , Crum, Brian A , Thompson, Matthew C , Pecina, Jennifer L.

Mayo Clinic

Health Services Research and Managerial Epidemiology | May 9, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23333928241253126 | PMID 38736506 Get It

Background Self-scheduling of medical visits is becoming more common but the complexity of applying multiple requirements for self-scheduling has hampered implementation. Mayo Clinic implemented self-scheduling in 2019 and has been increasing its portfolio of self-schedulable visits since then. Our aim was to show measures quantifying the complexity associated with medical visit scheduling and to describe how opportunities and challenges of scheduling complexity apply in self-scheduling. Methods We examined scheduled visits from January 1, 2022, through August 24, 2023. For seven visit categories, we counted all unique visit types that were scheduled, for both staff-scheduled and self-scheduled. We examined counts of self-scheduled visit types to identify those with highest uptake during the study period. Results There were 9555 unique visit types associated with 20.8 M (million) completed visits. Self-scheduled visit types accounted for 4.0% (838,592/20,769,699) of the completed total visits. Of seven visit categories, self-scheduled established patient visits, testing visits, and procedure visits accounted for 93.5% (784,375/838,592) of all self-scheduled visits. Established patient visits in primary care (10 visit types) accounted for 273,007 (32.6%) of all self-scheduled visits. Testing visits (blood and urine testing, 2 visit types) accounted for 183,870 (21.9%) of all self-scheduled visits. Procedure visits for screening mammograms, bone mineral density, and immunizations (8 visit types) accounted for 147,358 (17.6%) of all self-scheduled visits. Conclusion Large numbers of unique visit types comprise a major challenge for self-scheduling. Some visit types are more suitable for self-scheduling. Guideline-based procedure visits such as screening mammograms, bone mineral density exams, and immunizations are examples of visits that have high volumes and can be standardized for self-scheduling. Established patient visits and laboratory testing visits also can be standardized for self-scheduling. Despite the successes, there remain thousands of specific visit types that may need some staff-scheduler intervention to properly schedule.
Therapeutic biliary stents: applications and opportunities
Ledenko, Matthew , Toskich, Beau , Mehner, Christine , Ceylan, Hakan, Ceylan, Hakan , Patel, Tushar

Mayo Clinic

Expert Review of Medical Devices | May 8, 2024 | Volume: 21 | Issue: 5 | Pages: 399-409

10.1080/17434440.2024.2341960 | PMID 38716580 Get It

VITREORETINAL OUTCOMES FOLLOWING SECONDARY INTRAOCULAR LENS IMPLANTATION WITH PARS PLANA VITRECTOMY
Kaufmann, Gabriel T. , Gupta, Omesh P. , Yu, Julia , Lee, Crystal Y., Achuck, Kathryn, Hsu, Jason C. , Regillo, Carl D. , Garg, Sunir J. , Klufas, Michael A. , Mehta, Sonia , Cohen, Michael N. , Yonekawa, Yoshihiro , Starr, Matthew R , Nguyen, Michael K. , Achuck, Kathryn, Hsu, Jason, Ho, Allen C. , Xu, David N. , Kuriyan, Ajay E. , Starr, Matthew R.

Mayo Clinic

Retina | May 7, 2024 | Volume: 44 | Issue: 8 | Pages: 1337-1343

10.1097/iae.0000000000004139 | PMID 39047127 Get It

Background: Retrospective cohort study of 561 adult patients undergoing secondary intraocular lens (IOL) implantation by vitreoretinal surgeons at a single institution from April 2015 to December 2020. Methods: Patient historical factors, intraoperative/postoperative complications, and outcomes of IOL type (anterior chamber IOL versus scleral sutured IOL versus scleral fixated IOL versus. sulcus) were assessed. Primary outcomes were rates of postoperative retinal tears and rhegmatogenous retinal detachment. Secondary outcomes were rates of intraoperative endolaser, intraoperative retinal tear, and further IOL surgery. Results: The incidence of intraoperative retinal tears was 7.3% and not significantly different between techniques. Rates of intraoperative endolaser use were 17.5% among all techniques and not significantly different between techniques. Rates of postoperative retinal tear were low (0%–2.7%). Rates of postoperative rhegmatogenous retinal detachment were not significantly different between techniques (anterior chamber IOL 9/198 [4.5%], SFIOL 1/54 [1.9%], scleral sutured IOL 14/274 [5.1%], sulcus 2/35 [5.7%], total 26/561 [4.6%], P = 0.79). Rates of repeat IOL surgery trended higher in sulcus lenses (anterior chamber IOL 5/198 [2.5%], SFIOL 4/54 [7.4%], scleral sutured IOL 16/274 [5.8%], sulcus 5/35 [14.3%], total 30/561 [5.3%], P = 0.12). Conclusion: Intraoperative endolaser use and intraoperative retinal tear are not uncommon in secondary IOL surgery and underscore the importance of careful vitreoretinal management among these patients.
Infliximab Limits Injury in Myocardial Infarction
Livia, Christopher , Inglis, Sara S. , Crespo‐Diaz, Ruben , Rizzo, Skylar A. , Mahlberg, Ryan , Bagwell, Monique S , Hillestad, Matthew L. , Yamada, Satsuki , Siddharthan, Dhivya Vadhana Meenakshi , Singh, Raman Deep , Li, Xing , Arrell, D. Kent , Stalboerger, Paul G., Witt, Tyra A. , Sabbagh, Abdallah El , Rihal, Munveer, Rihal, Charanjit S. , Inglis, Sara S , Rizzo, Skylar A , Bagwell, Monique , Hillestad, Matthew , Meenakshi Siddharthan, Dhivya Vadhana , Stalboerger, Paul, Witt, Tyra , El Sabbagh, Abdallah , Rihal, Charanjit S. , Terzic, Andre , Bartunek, Jozef , Behfar, Atta , Mahlberg, Ryan C , Livia, Christopher , Terzic, André , Bartúnek, Jozef , Behfar, Atta

Mayo Clinic

Journal of the American Heart Association | May 3, 2024 | Volume: 13 | Issue: 9 | Pages: No page available

10.1161/jaha.123.032172 | PMID 38700022 Get It

Background The purpose of this study was to investigate a therapeutic approach targeting the inflammatory response and consequent remodeling from ischemic myocardial injury. Methods and Results Coronary thrombus aspirates were collected from patients at the time of ST‐segment–elevation myocardial infarction and subjected to array‐based proteome analysis. Clinically indistinguishable at myocardial infarction (MI), patients were stratified into vulnerable and resilient on the basis of 1‐year left ventricular ejection fraction and death. Network analysis from coronary aspirates revealed prioritization of tumor necrosis factor‐α signaling in patients with worse clinical outcomes. Infliximab, a tumor necrosis factor‐α inhibitor, was infused intravenously at reperfusion in a porcine MI model to assess whether infliximab‐mediated immune modulation impacts post‐MI injury. At 3 days after MI (n=7), infliximab infusion increased proregenerative M2 macrophages in the myocardial border zone as quantified by immunofluorescence (24.1%±23.3% in infliximab versus 9.29%±8.7% in sham; P <0.01). Concomitantly, immunoassays of coronary sinus samples quantified lower troponin I levels (41.72±7.34 pg/mL versus 58.11±10.75 pg/mL; P <0.05) and secreted protein analysis revealed upregulation of injury‐modifying interleukin‐2, ‐4, ‐10, ‐12, and ‐18 cytokines in the infliximab‐treated cohort. At 4 weeks (n=12), infliximab treatment resulted in significant protective influence, improving left ventricular ejection fraction (53.9%±5.4% versus 36.2%±5.3%; P <0.001) and reducing scar size (8.31%±10.9% versus 17.41%±12.5%; P <0.05). Conclusions Profiling of coronary thrombus aspirates in patients with ST‐segment–elevation MI revealed highest association for tumor necrosis factor‐α in injury risk. Infliximab‐mediated immune modulation offers an actionable pathway to alter MI‐induced inflammatory response, preserving contractility and limiting adverse structural remodeling.